Gland Pharma Q4 FY26 Investor Presentation: Revenue Up 22%, Adj. PAT Up 97%
Gland Pharma reported Q4 FY26 consolidated revenue of ₹17,428 crore, up 22% YoY. Adj. PAT surged 97% to ₹3,667 crore. FY26 revenue was ₹64,307 crore, up 14%, with Adj. PAT at ₹10,455 crore, up 50%. The company launched five molecules in the US in Q4 FY26 and plans facility upgrades in August 2026. A final dividend of ₹20 per share is recommended.
The announcement details robust financial results with substantial revenue and profit growth, alongside strategic business updates including new product launches and facility expansions, which are material to investors.
The company reported strong year-on-year growth in revenue and a significant increase in adjusted profit after tax for both the quarter and the full fiscal year, along with positive business updates and expansion plans.
Gland Pharma Limited has released its investor presentation for the fourth quarter and full fiscal year 2026, detailing significant financial performance and business updates.
For the fourth quarter of FY26, the company reported a consolidated revenue from operations of ₹17,428 crore, marking a 22% year-on-year increase from ₹14,249 crore in Q4 FY25. Adjusted Profit After Tax (Adj. PAT) saw a substantial surge of 97%, reaching ₹3,667 crore compared to ₹1,865 crore in the prior year's corresponding quarter. The Adj. PAT margin improved to 21% from 13% in Q4 FY25. Adjusted EBITDA also grew by 51% to ₹5,244 crore.
For the full fiscal year 2026, consolidated revenue from operations grew by 14% to ₹64,307 crore, while Adj. PAT increased by 50% to ₹10,455 crore. The Adj. PAT margin for FY26 stood at 16%.
The base business (Gland) also demonstrated strong growth, with Q4 FY26 revenue from operations increasing by 22% to ₹12,648 crore. Adj. PAT for the base business rose by 45% to ₹4,211 crore in Q4 FY26. For the full year FY26, base business revenue grew by 11% to ₹45,613 crore, and Adj. PAT increased by 22% to ₹13,232 crore.
Key business updates include R&D expenses of ₹506 million in Q4 FY26, focusing on complex product development. The company launched five new molecules in the USA in Q4 FY26, including Dalbavancin and Brimonidine, with 31 products launched in the USA during FY26. Gland Pharma filed eight ANDAs and received approvals for 11 in Q4 FY26, contributing to a cumulative total of 388 ANDA filings in the U.S. (337 approved).
Significant developments at the Fontenay facility include the ramp-up of a new ampoule filling line and plans to replace an old line with a new high-capacity one in August 2026, aiming to add 30 million ampoule capacity by 2027. The Hérouville facility continued its production ramp-up for two products launched in 2025. The Braine-l'Alleud & Osny sites maintained momentum, with Braine securing a new hormonal PFS contract.
Cenexi's performance was robust, with Q4 FY26 revenue from operations at €45 crore (₹4,780 crore), a 22% year-on-year increase. For the full year FY26, Cenexi's revenue was €182 crore (₹18,693 crore), up 25% year-on-year.
Geographically, the US market contributed significantly, with Gland's revenue in the US standing at ₹9,807 crore in Q4 FY26 and ₹34,214 crore for FY26. Europe's contribution was ₹3,814 crore in Q4 FY26 and ₹14,035 crore for FY26, driven by Cenexi's momentum. Other core markets and Rest of World also showed positive contributions.
The Board of Gland Pharma has recommended a final dividend of ₹20 per equity share for FY26, subject to shareholder approval.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.